This Study performs unique rapid on-site measurement using patient whole blood and positions Company to move forward with multiple initiatives ACTON, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Bluejay ...

ACTON, Mass., May 19, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform ...

An update from Bluejay Diagnostics ( ($BJDX) ) is now available. On December 29, 2025, Bluejay Diagnostics announced it had completed ...

This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. ACTON, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bluejay ...

RARITAN, N.J., July 22, 2021 /PRNewswire/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced its VITROS (R) ...

Neonatal sepsis is a leading cause of death for newborns Testing IL-6 can indicate a neonatal sepsis infection earlier than other biomarkers Earlier diagnosis of neonatal sepsis can lead to improved ...

Based on current antibody inventory, Bluejay estimates that it has sufficient material to support production of more than nine million Symphony cartridges for clinical and commercial manufacturing ...

Basel, 04 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorisation (EUA) for the Elecsys® IL-6 test.